首页> 外国专利> MONOVALENT LOSBANOS VACCINE AGAINST LOCALLY PREVALENT LEPTOSPIRA SEROVAR IN THE PHILIPPINES

MONOVALENT LOSBANOS VACCINE AGAINST LOCALLY PREVALENT LEPTOSPIRA SEROVAR IN THE PHILIPPINES

机译:菲律宾本地流行的地方性钩端螺旋体疫苗

摘要

The present technology relates to processes of preparing leptospirosis vaccines against serovars or serotypes of Leptospira prevalent in the Philippines. Three types of inactivated vaccines were developed based on two identified most prevalent pathogenic Leptospira serovars circulating in the Philippines, namely, Manilae and Losbanos. The vaccines that have been developed are: (1) Monovalent Manilae, (2) Monovalent Losbanos, and (3) Bivalent Manilae and Losbanos (homologous challenge with serovars Manilae and Losbanos and heterochallenge with serovar Grippotyphosa and serovar Canicola). The vaccines that were produced through the developed process were assessed on their safety, immunogenicity and efficiency. The main advantage of these vaccines is their serovar-specificity for the pathogenic Leptospira serovars that are locally prevalent which would ensure an effectively directed program of preventive control of leptospirosis in animals which can be translated to effective leptospirosis prevention among humans.
机译:本技术涉及制备针对菲律宾流行的血清型或钩端螺旋体血清型的钩端螺旋体病疫苗的方法。根据在菲律宾流通的两种最流行的致病性钩端螺旋体血清型,开发了三种类型的灭活疫苗,即马尼拉和洛斯巴诺斯。已开发的疫苗是:(1)单价马尼拉病毒,(2)单价马尼拉病毒和(3)二价马尼拉病毒和Losbanos(与血清型马尼拉病毒和Losbanos同源攻击,并与血清型Grippotyphosa和血清型Canicola异源攻击)。通过开发的过程生产的疫苗经过了安全性,免疫原性和效率评估。这些疫苗的主要优点是它们对局部流行的致病性钩端螺旋体血清型具有血清特异性,这将确保在动物中对钩端螺旋体病进行预防性控制的有效指导方案,从而可以在人类中有效地预防钩端螺旋体病。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号